📊 INO Key Takeaways
Is Inovio Pharmaceuticals, Inc.. (INO) a Good Investment?
Inovio is in severe financial distress with zero revenue, significant accumulated operating losses, and a debt burden ($62.8M) exceeding total assets ($49.8M). With negative operating cash flow of -$21.6M annually and only $26.3M in cash, the company has approximately 14 months of runway before capital depletion at current burn rate, making it unsuitable for fundamental investors.
INOVIO’s fundamentals are very weak: revenue is negligible and shrinking sharply, while operating losses and free cash outflow remain extremely large relative to its asset base and equity. Although net loss and EPS improved year over year, the improvement appears to come off a deeply unprofitable base and does not offset the company’s poor growth quality, leveraged balance sheet, and limited cash runway without stronger commercialization or financing support.
Why Buy Inovio Pharmaceuticals, Inc.. Stock? INO Key Strengths
- Retains $26.3M in cash providing near-term liquidity buffer
- Operating losses moderating slightly year-over-year (EPS loss improvement)
- Insider trading activity suggests management engagement in company direction
- Cash balance of $44.27M still provides some near-term operating flexibility
- Current and quick ratios of 1.40x indicate no immediate liquidity collapse
- Net loss and diluted EPS improved year over year, showing some cost or non-operating loss reduction
INO Stock Risks: Inovio Pharmaceuticals, Inc.. Investment Risks
- Zero revenue with -70% YoY decline indicates failed commercialization or pre-revenue stage
- Liabilities ($43.7M) nearly consume all assets ($49.8M) with minimal equity cushion of $6.1M
- Debt/Equity ratio of 10.34x and interest coverage of -123.4x indicate inability to service debt from operations
- Negative operating cash flow of -$21.6M annually with ~14 months cash runway at current burn rate
- Balance sheet insolvency risk requiring debt restructuring, dilutive equity financing, or asset liquidation
- Revenue base is extremely small at $65.34K and declined 70.0% year over year, indicating very weak commercialization
- Operating cash flow of -$88.63M and free cash flow of -$88.92M suggest heavy cash burn relative to available cash
- Debt/equity of 2.60x, negative ROE of -352.5%, and long-term debt of $62.76M point to stressed financial health
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue reactivation or achievement of any commercial milestones
- Debt restructuring announcements or covenant violations
- Operating cash flow inflection toward sustainability
- Stockholders equity trajectory amid accumulated losses
- Quarterly operating cash burn versus cash and equivalents
- Meaningful revenue growth from product commercialization or partnership inflows
Inovio Pharmaceuticals, Inc.. (INO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Inovio Pharmaceuticals, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
INO Profit Margin, ROE & Profitability Analysis
INO vs Healthcare Sector: How Inovio Pharmaceuticals, Inc.. Compares
How Inovio Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inovio Pharmaceuticals, Inc.. Stock Overvalued? INO Valuation Analysis 2026
Based on fundamental analysis, Inovio Pharmaceuticals, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inovio Pharmaceuticals, Inc.. Balance Sheet: INO Debt, Cash & Liquidity
INO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inovio Pharmaceuticals, Inc..'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
INO Revenue Growth, EPS Growth & YoY Performance
INO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$19.7M | $-0.28 |
| Q3 2025 | N/A | -$19.7M | $-0.87 |
| Q2 2025 | N/A | -$19.7M | $-0.61 |
| Q1 2025 | N/A | -$19.7M | $-0.51 |
| Q3 2024 | N/A | -$25.2M | $-0.89 |
| Q2 2024 | $100.8K | -$30.5M | $-1.19 |
| Q1 2024 | N/A | -$30.5M | $-1.31 |
| Q3 2023 | $388.4K | -$33.9M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inovio Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
INO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inovio Pharmaceuticals, Inc.. (CIK: 0001055726)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INO
What is the AI rating for INO?
Inovio Pharmaceuticals, Inc.. (INO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INO's key strengths?
Claude: Retains $26.3M in cash providing near-term liquidity buffer. Operating losses moderating slightly year-over-year (EPS loss improvement). ChatGPT: Cash balance of $44.27M still provides some near-term operating flexibility. Current and quick ratios of 1.40x indicate no immediate liquidity collapse.
What are the risks of investing in INO?
Claude: Zero revenue with -70% YoY decline indicates failed commercialization or pre-revenue stage. Liabilities ($43.7M) nearly consume all assets ($49.8M) with minimal equity cushion of $6.1M. ChatGPT: Revenue base is extremely small at $65.34K and declined 70.0% year over year, indicating very weak commercialization. Operating cash flow of -$88.63M and free cash flow of -$88.92M suggest heavy cash burn relative to available cash.
What is INO's revenue and growth?
Inovio Pharmaceuticals, Inc.. reported revenue of $0.0.
Does INO pay dividends?
Inovio Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find INO SEC filings?
Official SEC filings for Inovio Pharmaceuticals, Inc.. (CIK: 0001055726) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INO's EPS?
Inovio Pharmaceuticals, Inc.. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INO a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Inovio Pharmaceuticals, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INO stock overvalued or undervalued?
Valuation metrics for INO: ROE of -324.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INO stock in 2026?
Our dual AI analysis gives Inovio Pharmaceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INO's free cash flow?
Inovio Pharmaceuticals, Inc..'s operating cash flow is $-21.6M, with capital expenditures of $0.0.
How does INO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -324.4% (avg: 15%), current ratio 1.04 (avg: 2).
Is Inovio Pharmaceuticals, Inc.. carrying too much debt?
INO has a debt-to-equity ratio of 10.34x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.04 suggests adequate short-term liquidity.